Related Experiment Video
Updated: Jun 20, 2026
07:56
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
Published on: November 11, 2020
Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles
Moritz Beck-Broichsitter1, Julia Gauss, Tobias Gessler
1Medical Clinic II, Department of Internal Medicine, Justus-Liebig-University Giessen, Klinikstrasse 36, D-35392 Giessen, Germany.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|September 26, 2009
Summary
Biodegradable polymeric nanoparticles offer a promising approach for pulmonary drug delivery. This study shows that novel VS(72)-10 nanoparticles provide sustained release of salbutamol, improving lung absorption compared to traditional solutions.
Area of Science:
- Nanomedicine
- Pulmonary Drug Delivery
- Polymeric Nanoparticles
Background:
- Aerosol therapy utilizes particulate drug carriers for lung delivery of therapeutic compounds.
- Polymeric nanoparticles are extensively researched nanomedicine carriers.
- Targeted and controlled drug release from nanoparticles for pulmonary delivery remains underexplored.
Purpose of the Study:
- To compare pulmonary absorption and distribution of salbutamol.
- To evaluate salbutamol aerosolized as a solution versus entrapped in novel polymeric nanoparticles.
- To assess characteristics in an isolated rabbit lung model (IPL).
Main Methods:
- Preparation and characterization of salbutamol-loaded PLGA and VS(72)-10 nanoparticles.
- Assessment of physicochemical properties, morphology, encapsulation efficiency, and in vitro drug release.
- Evaluation of nanoparticle stability to nebulization and pulmonary drug absorption/distribution in an IPL.
Main Results:
- VS(72)-10 nanoparticles exhibited higher salbutamol encapsulation efficiency (63.4%) and stability post-nebulization compared to PLGA nanoparticles.
- In vitro and in vivo studies demonstrated sustained salbutamol release from VS(72)-10 nanoparticles.
- Lower salbutamol recovery in perfusate from VS(72)-10 nanoparticles indicated improved pulmonary absorption.
Conclusions:
- Inhalative delivery of biodegradable nanoparticles is a viable strategy for respiratory disease treatment.
- VS(72)-10 nanoparticles show potential for enhanced pulmonary drug delivery.
- Further research into nanoparticle-based aerosol therapy is warranted.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...